Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The ...

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...

A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma." ...